Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ8808MR)

This product GTTS-WQ8808MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	2-Thio-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_005018.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	5133
UniProt ID	Q15116

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8808MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15265MR	IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	Tarvacin ch3G4
GTTS-WQ9342MR	IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	INCAGN-01876
GTTS-WQ15938MR	IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	ZTS-00084768
GTTS-WQ14250MR	IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	RG-7116
GTTS-WQ2382MR	IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	AMG 102
GTTS-WQ11390MR	IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	MEDI-575
GTTS-WQ11236MR	IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MEDI3902
GTTS-WQ14646MR	IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	SC0001-SCX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST